Search

Bromopyruvate

Pozelimab

autoimmune hemolysis that are often observed in CHAPLE disease. … CD55-deficient protein-losing enteropathy (PLE), or CHAPLE disease, is an ultra-rare hereditary disease, with fewer than 100 patients diagnosed worldwide or fewer than 10 patients in the US.

DDP-225

The unique combination of noradrenaline reuptake inhibition and 5-HT3 antagonism in one orally delivered compound represents a novel approach to treating IBS-d and other functional GI diseases. … Dynogen licensed preclinical and clinical data related to DDP225 from Mitsubishi Pharma in October 2003.

ONT-093

In pre-clinical studies, ONT-093 could inhibit P-gp and reverse multidrug resistance at nM concentrations with no effect on paclitaxel pharmacokinetics. … ONT-093 is an orally bioavailable inhibitor of P-glycoprotein (P-gp).

Biomed 101

Biomed 101 is investigated for use/treatment in adverse effects (chemotherapy) and renal cell carcinoma. Biomed 101 is a solid.

ALTU-135

This consistent and pure enzyme combination is designed to improve fat, protein and carbohydrate absorption in pancreatic insufficient individuals.

13-deoxydoxorubicin

GPX-100 is an anthracycline anticancer drug that belongs to the family of drugs called antitumor antibiotics.

Lancovutide

Lancovutide, a peptide antibiotic, is in clinical development for the treatment of cystic fibrosis.

Tubocurarine

[A216028] It was first isolated by Harold King in 1935 and was used clinically to induce neuromuscular blockade during surgeries, particularly those involving the abdomen. … [A216048] Safer and more pharmacokinetically favorable non-depolarizing neuromuscular blockers, such as [rocuronium], have largely replaced the use of tubocurarine in the clinical setting.[A216048]

ALKS 27

ALKS 27 is an inhaled formulation of trospium chloride for the treatment of chronic obstructive pulmonary disease (COPD).